CertaraCERT
CERT
About: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Employees: 1,546
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
137% more call options, than puts
Call options by funds: $596K | Put options by funds: $251K
62% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 34
46% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 63
8% more funds holding
Funds holding: 222 [Q4 2024] → 240 (+18) [Q1 2025]
3.42% more ownership
Funds ownership: 72.27% [Q4 2024] → 75.69% (+3.42%) [Q1 2025]
3% less capital invested
Capital invested by funds: $1.24B [Q4 2024] → $1.21B (-$32.5M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
18%
upside
Avg. target
$15
36%
upside
High target
$18
63%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Barclays Luke Sergott | 27%upside $14 | Overweight Upgraded | 8 May 2025 |
Keybanc Scott Schoenhaus | 63%upside $18 | Overweight Maintained | 16 Apr 2025 |
Baird Joe Vruwink | 18%upside $13 | Neutral Maintained | 11 Apr 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Joe Vruwink - Baird Scott Schoenhaus - KeyBanc Capital Markets David Windley - Jefferies Dan Leonard - UBS Jeff Garro - Stephens Christine Rains - William Blair Constantine Davides - Citizens Operator Good day, and thank you for standing by. Welcome to the Certara First Quarter 2025 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.10 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Certara Reports First Quarter 2025 Financial Results
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025.
Neutral
GlobeNewsWire
1 month ago
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Neutral
Zacks Investment Research
1 month ago
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Negative
MarketBeat
1 month ago
3 Momentum Stocks That Could Soar Post-Market Volatility
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
Positive
Benzinga
2 months ago
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.
Neutral
GlobeNewsWire
2 months ago
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies.
Positive
Seeking Alpha
2 months ago
Buy Certara After The FDA Announcement
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials.
Positive
Zacks Investment Research
2 months ago
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Charts implemented using Lightweight Charts™